Skin substitutes are crucial for treating deep wounds. While autologous substitutes are ideal, their generation is hindered by limited donor supply and lengthy production processes.

Our solution involves engineering a novel biomimetic skin matrix using genetically modified human dermal cells with self-limited growth. This innovation aims to produce a universally accepted skin substitute, minimizing immune rejection and expediting scarless wound healing.

The development of a non-rejectable, readily available allogenic skin substitute promises a game-changing approach to treating acute and chronic wounds, paving the way for authentic skin regeneration.